Frontiers issues a correction to a pirfenidone review in fibrotic lung disease
Frontiers in Medicine has published a correction to the review “Use of pirfenidone in fibrotic interstitial lung diseases and beyond: a review.” The notice appears in the Respiratory Medicine section and carries DOI 10.3389/fmed.2026.2019848. It was received on 6 October 2026 and accepted on 15 October 2026.
Corrections like this are not peripheral editorial footnotes. In a field where treatment decisions hinge on how quickly fibrosis progresses, how adverse events are framed, and which disease subtypes are grouped together, even a small textual amendment can matter to clinicians reading for practical guidance.
The correction concerns a review centered on pirfenidone, the antifibrotic agent frequently discussed in the setting of fibrotic interstitial lung diseases. The article’s keywords place the discussion squarely in the territory of adverse events, CTD-ILD, fibrotic interstitial lung diseases, pirfenidone, and post-COVID-19 pulmonary fibrosis. Those terms sketch the therapeutic frame with unusual clarity: a drug that has already become familiar in idiopathic pulmonary fibrosis is being considered across a broader fibrotic spectrum where inflammation, immune activation, and persistent tissue remodeling can overlap.
One sentence can carry the entire practical weight of such a correction: the record has been amended, and readers must now interpret the review through the updated version.
Pirfenidone sits at the center of expanding antifibrotic use
Pirfenidone remains clinically relevant because fibrosis in the lung is not a single disease process. In connective tissue disease-associated interstitial lung disease, post-infectious fibrosis, and other fibrotic syndromes, the pathological endpoint may look similar even when the upstream biology differs. Fibroblast activation, excess extracellular matrix deposition, and progressive loss of normal alveolar architecture are the common threats; the trigger can be autoimmune, post-viral, idiopathic, or mixed.
That biological overlap explains why reviews of pirfenidone attract attention well beyond a narrow specialty audience. When a medication is discussed “in fibrotic interstitial lung diseases and beyond,” the message to pulmonologists, rheumatologists, and general clinicians is straightforward: the therapeutic question is no longer limited to one named diagnosis. It now includes whether a single antifibrotic strategy can help across disease categories that share a fibrosing phenotype but differ in trajectory and tolerability.
The correction notice does not provide the specific error being amended, and it does not restate the underlying review’s conclusions. Even so, the publication itself signals an important editorial reality. Reviews are often used as a secondary source for practice-pattern formation, and any amendment to the text can influence how readers weigh adverse events, interpret disease-specific nuance, or integrate pirfenidone into broader pulmonary fibrosis discussions.
Adverse events remain central to how pirfenidone is used at the bedside
The inclusion of adverse events among the listed keywords points to one of the most clinically sensitive aspects of pirfenidone use. Antifibrotic benefit only matters if treatment can be sustained, and sustained treatment depends on whether patients can tolerate the drug long enough to derive value from it. In routine care, the gap between efficacy and usability is often filled by nausea, gastrointestinal upset, photosensitivity, or dose adjustment strategies, all of which shape persistence in the real world.
In fibrotic lung disease, the bedside calculus is especially unforgiving. Patients may already have reduced exercise capacity, cough, hypoxemia, or coexisting autoimmune disease; adding a medication with tolerability constraints demands careful follow-up. A review that spans multiple fibrotic entities therefore needs precision not only about mechanism but also about the practical burden of treatment. If a correction touches any part of that framing, clinicians have reason to recheck the revised text before relying on it in teaching or prescribing discussions.
Post-COVID-19 pulmonary fibrosis keeps the field under pressure
The appearance of post-COVID-19 pulmonary fibrosis among the keywords shows how quickly the antifibrotic conversation has widened. Persistent radiographic abnormalities after viral lung injury have kept fibrosis on the agenda, even as the field continues to sort out which patients truly progress and which stabilize over time. Pirfenidone sits in that conversation because it is one of the better-known antifibrotic agents available for consideration when scarring rather than active infection dominates the clinical picture.
This is where the pathophysiology becomes more than background. Fibrosis after lung injury is a process of aberrant repair, not simple inflammation. Once the reparative response becomes self-sustaining, the therapeutic logic shifts from symptom control to slowing structural decline. That is the niche into which pirfenidone is commonly placed, and it is exactly why reviews of its use attract scrutiny from respiratory clinicians looking for careful separation of mechanism, evidence, and adverse-event burden.
The correction notice does not reveal whether the amendment affects efficacy statements, safety language, or citation details. Still, the presence of a correction in a review that spans fibrotic interstitial lung disease and post-COVID-19 fibrosis reinforces a basic editorial lesson: precision in this literature is not cosmetic. It governs how clinicians interpret a drug that is increasingly discussed across overlapping pulmonary phenotypes.
What the correction means for readers of the review
For readers returning to the original review, the immediate action is simple: consult the corrected version before citing or applying it. That is especially important in a topic where the boundaries between idiopathic fibrosis, connective tissue disease-related fibrosis, and post-viral fibrosis are still being defined in practice. Reviews often serve as the bridge between mechanistic understanding and clinical decision-making, so any update to that bridge deserves attention.
The correction also signals the value of transparency in respiratory medicine publishing. A formally issued amendment preserves the integrity of the literature and gives clinicians a cleaner reference point when discussing pirfenidone with patients, especially those balancing potential antifibrotic benefit against the reality of chronic therapy. In diseases marked by gradual decline, there is little margin for ambiguity in how the evidence is presented.
The notice does not add new trial data, new patient outcomes, or new comparative efficacy findings. Its importance lies elsewhere: in restoring the accuracy of a review that sits at the intersection of fibrotic lung biology, treatment tolerability, and a rapidly expanding set of clinical indications. For a field still sorting out how broadly antifibrotic therapy should travel, even a correction deserves a careful read.